Just when we thought it was over-ambiguity pops it head-Still a legality challenge of hESC federal funding
October 18th, 2012
No comments
Sherley vs Sebelius’, hESC suit kicked to Supreme Court … Read more…
Archive
Archive for the ‘Sherley v. Sebelius case’ Category
Stem-cell Arguments continue to be heard in US appeals court
Another step in and slow but steady path to the US Supreme Court Read more…
Sherley v. Sebelius Stem Cell Case, additional Legal Arguments Filed
Genetics Policy Institute (GPI) files <further> Amicus Briefs Read more…
Judge Dismisses Suit on Federal Stem Cell Research
Judge Royce Lamberth, chief of the federal court in Washington is throwing out a lawsuit challenging the Obama administration’s funding of embryonic stem cell research. Read more…
Embryonic Stem-Cell (hESC) Funding Challenge should be dismissed
A challenge to funding of hESC studies should be dismissed after an appeals court found the government-backed research to be lawful, Read more…
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
Mastering the origins of conviction, one key stroke at a time
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.
Recent Posts
- Volatility and lethargy rule the Friday close
- Advanced Cell Technology (OTCBB: ACTC) Q1/13 Results, how many shares doesn’t it take to light a beacon – 2.39 billion?
- Every day is an investment
- Neuralstem (NYSE MKT: CUR) Q1/13 Results – SELL – can’t argue with recent appreciation but how long will it last?
- The Early Movers – who’s hot, who’s not
Categories
- $16.7M to Fund CLT-008 for ARS
- $3M Award to Develop Gene
- 18 month outcomes from its APOLLO trial
- A Daily Look
- A prayer for those dead
- Aastrom Biosciences
- Aastrom Biosciences (ASTM)
- Acquisition
- ACTC.OB
- ACTCellerate™ Cell Lines
- Acute Mycardial Infaraction (AMI) Update and Review
- Acute Radiation Syndrome (ARS)
- Adam Feuerstein
- adult stem cells
- Advanced Cell Technology
- Advanced Cell Technology (ACTC.OB)
- advocacy coalition
- AFIRM
- AHA Update
- Alchemia (ASX: ACL)
- Aldagen
- Aldargen
- Alliance Defense Fund
- Allogeneic cell-based therapy
- ALS Clinical Trial
- Alzheimer's disease
- AMEX: BTX
- AMEX: CUR
- AMEX: NBS
- Amicus Brief
- Amicus Curiae Filing
- An Expanded Market Oppurtunity
- An extra $1B for the NIH?
- An Objective Opinion
- Anaplastic Thyroid Cancer
- AnC Bio Holdings
- Angelman Syndrome
- Angiochem
- APOLLO study
- APOLLO Trial demonstrated Safety & Feasibility and Improvements in Cardiac Function
- ASTM
- ASX: MSB
- At-the-Market (ATM) Offerings
- Athersys (ATHX)
- Athersys (NASDAQ: ATHX)
- Autologous cell therapy
- basal cell carcinomas (BCCs)
- Batten disease
- BAXTER
- Baxter Ventures
- BBRI
- Bio Medicine
- Bioheart (OTCBB: BHRT)
- BioLife Solutions (OTC BLFS)
- Biomedical CEO survey
- Biomet Biologics
- BioMimetic Therapeutics
- BioMimetic Therapeutics (BMTI)
- Biopolymer Microthreads
- BioRestorative Therapies (OTC: BRTXD)
- Biotech Leads by Percentage in Q/2/10
- Biotechnology Tax Breaks
- BioTime (AMEX:BTX)
- BioTime (NYSE MKT: BTX)
- BLA Approval
- Bluebird bio
- Board of Director's appointment
- Boston Biomedical Research Institute
- Brainstorm Therapeutics (BCLI.OB)
- Breaking News
- Bright Cell Therapy Study funded by NHLBI/NIH
- California Institute for Regenerative Medicine (CIRM)
- cancer
- Cancer Costs to rise as US Population Ages
- cancer research
- cancer stem cells
- Capricor
- CAR Gene
- Cardiac Cell Therapy webcast
- Cardio3 BioSciences
- Cardiovascular Licensing Agreement
- Cedars-Sinai Regenerative Medicine Institute
- Cell Therapy Companies
- Cellectis SA to acquire Cellartis
- Cellerant Therapeutics
- Cellular Dynamics
- Cellular origins of breast cancer
- Cephalon (CEPH)
- Cevec Pharmaceuticals
- Chemistry Nobel Prize
- Clinical Data from GRNOPC1 Spinal Cord Injury Trial
- Clinical Hold Lifted
- Clinical Trial for DCM
- Clinical Trial for multiple sclerosis-related fatigue (PMSF)
- Co-promotion Sales Agreement
- Collaboration
- Collaboration and License Agreement
- Collaborative Research
- Colon Cancer and detecting Relapse
- Columbia University Medical Center
- commercial sale in India
- Common Stock Exchange for 12/10 Warrants
- Complete sequencing of DNA shows normality of the cells and their suitability for clinical use
- Cord Blood Banks
- Cord Blood Stem Cell Adaptation
- Cord Blood Stem Cells
- Credit Downgrade
- critical limb ischemia
- Crohn's Disease Colitis Model
- Cytomedix (OTC BB:CMXI)
- Cytomedix (OTC QX: CMXI)
- Cytori Therapeutics
- Cytori's PRECISE trial
- Cytovis
- CYTX
- CYTX – Strong BUY
- CYTX earnings call
- CYTX Shareholder Letter
- Daily Look EOD Closing Bell
- Daily Look Starting the Day
- Death of Chairman and CEO
- Defense Advanced Research Projects Agency (DARPA)
- Definitive Merger Agreement
- Dendreon (DNDN)
- Diabetes
- Dickey-Wicker amendment
- Divestiture of Ownership Interest in Suzhou Erye closes
- DOD Award to treat Osteoporosis
- DOD Contract for Brain Cancer Research
- Dosing of HuCNS-SC in PMD Trial completed
- Dr. Robin Smith
- Drug and device reviews
- Dry AMD
- Early-stage Phase I trial
- Earnings Conference Call
- Earnings Report Card
- EB66 duck stem cell technology
- Edward P. Owens
- effective treatment for malignant glioma
- elimination and reductions of debt
- embryonic stem cell research
- Encapsulation and Stem Cell Technologies
- Epigenetics
- equity investment of $7.1M
- EU CE Mark
- European Medicines Agency (EMA)
- Exclusive license agreement
- Expands P2 Trial of ICT-107
- Extension of Warrant Expiration Date
- Fate Therapeutics
- FDA Approves First Cord Blood Product
- FDA Clearance for P3 Bone Marrow Transplant Trial
- FDA Fast Track Designation
- Federal funding of human embryonic stem cell (hESC) research
- Fetal stem cell transplants
- Fibrocell Science
- Finalizes Amorcyte Acquisition
- Financing
- financings
- First ADVANCE trial site to begin enrollment in the Netherlands
- First Clinical Trial using hESCs
- First Patients enrolled in 2 Clinical Trials to treat Stargardt's Disease and Dry Age Macular Degeneration
- Food and Drug Administration (FDA)
- Forecast Issues
- FOXM1 gene
- French Muscular Dystrophy Association (AFM)
- Fresenius Biotech
- Fresenius Biotech’s ATG
- Frozen Blood from Stored Samples
- Fy10 earnings and recap
- FY10 Results
- FY11 & FY12 Achievements and Highlights
- FY11 Results
- FY12 Achievements and Highlights
- Gene Test finds Disease Risk
- Gene Therapy
- Generating Platelets using iPSCs
- Generation of functional dopaminergic neuronal cells
- Genetic Mechanism
- Genetics Policy Institute (GPI)
- GERN
- Geron (GERN)
- GRABM-L (GR N1005 against B rain M etastases – L ung cancer)
- Grant for type 1 diabetes research
- GRN1005 P2 Trial
- GRN163L preclinical data
- Growing back a damaged spine
- Growing blood vessels from human tissues
- Growing heart cells
- Growing New Replacement Joints
- Guidance
- H.R. 6165
- Haemopoietic Stem Cells
- Hamilton Thorne Ltd. (TSX-V: HTL)
- Happy New Year 2011
- Happy New Year 2012
- Happy New Year 2013
- Happy Thanksgiving
- Harris Interactive/HealthDay poll
- Harvard Apparatus Regenerative Technology
- Harvard Bioscience (HBIO)
- Harvard Scientists Report
- Harvest Technologies’
- Healthcare
- Healthcare VC continues to Slide
- Heated gold nanoshells
- HemoGenix®
- Henry McCusker
- Henry W McCusker
- hESC development
- hESC funding Controversy
- hESCs to treat SMD
- Histogenics
- HIV Therapy Findings
- Holiday Achievement
- House Republicans
- HR 6081
- HR 6081 Renewed
- http://www.scimitarequity.com/blog/wp-admin/user-new.php
- Human Cardiomyocyte Product Launches
- Human Stem Cells used to treat Parkinson's
- IBD Phase II Clinical Trial
- IDE clinical trial
- imetelstat (GRN163L)
- Immune Matched Human Parthenogenetic Stem Cells
- ImmunoCellular Therapeutics
- IMUC.OB
- In-house screening of compound libraries
- In-License of Patent Portfolio
- IND Application Cleared
- IND Approval for Major Depression Trial
- IND Filed
- IND for SMD
- Independent Equity Research
- Independent Insight
- induced pluripotent stem (iPS) cells
- Induced pluripotent stem cell lines
- induced pluripotent stem cells technology
- initiates P2 Trial of GRN1005
- Initiates PSTI with a Speculative "BUY" rating
- Initiation Phase II Trial
- intellectual property deals
- IntelliCell (OTCQB: SVFC)
- Interim Results
- Interim results from ASTM’s US Phase 2b RESTORE-CLI trial
- International Stem Cell (ISCO.OB)
- Intestinal Tissue
- iPierian
- iPS Cell Patent in-licensed
- iPS Cell Patents
- iPS-derived heart cells
- IRB Approval
- Is Dilution the only Solution?
- ischemic stroke
- Ischemic Tolerant Stem Cells
- ISCO.OB
- James Sherley
- Join our Community
- Joint Venture
- Juventas Therapeutics
- Karolinska Institutet
- Key Catalysts and Milestones
- Key factors driving growth in stem cells research
- Lack of Funding Stability
- leukemia
- License
- Licenses a clinically active oncology vaccine
- Life Sciences Jobs and Investment Act of 2010
- Life Technologies Corporation (NASDAQ: LIFE)
- Lifeline Skin Care ™.
- Lin28
- livers from stem cells
- LON: RENE
- Long QT syndrome
- Macular Degeneration
- Major Luis Alvarez
- Management Change
- Marketing Agreement
- Maryland Stem Cell Research Commission issues 2012 Requests for Applications (RFAs)
- Maryland Stem Cell Research Fund
- Mass Companies
- Matched maternal blood cells
- Material Transfer Agreement
- Medical College of Wisconsin
- Medistem (MEDS.PK)
- Medtronic (MDT) participated
- MELA Sciences (MELA)
- Memorandum of Understanding
- Merger Agreement
- Merger Negotiations Terminated
- Merger of Glycosan BioSystems
- Merry Christmas
- Mesoblast (ASX: MSB)
- Mesoblast Ltd
- Michael J. Fox Foundation
- Miltenyi Biotec
- miR-34a
- Mirna Therapeutics
- Momentum and Appreciation
- Motor Neurone Disease Research
- MSC's
- MultiStem
- MultiStem therapy for treating stroke
- Muscular Dystrophy
- Myoblast program
- NANEX
- NASDAQ Compliance
- NASDAQ Listing Issue
- NASDAQ: ACTC.OB
- NASDAQ: ASTM
- NASDAQ: ATHX
- Nasdaq: BCLI.OB
- NASDAQ: BMTI
- NASDAQ: CYTX
- NASDAQ: FSC.OB
- NASDAQ: GERN
- NASDAQ: IMUC.OB
- NASDAQ: ISCO.OB
- NASDAQ: KOOL
- NASDAQ: LFE
- NASDAQ: OSIR
- NASDAQ: PSTI
- NASDAQ: STEM
- NASDAQ: STEMD
- NASDAQ: TNGN
- NASDAQ:OPXA
- National Institute of Health(NIH)
- National Securities
- National Securities Corp
- National Securities Downgrade
- National Venture Capital Association (NVCA)
- Nature Biotechnology article
- NBS and Progenitor Cell Therapy (PCT) closed their merger transaction.
- NBS’s Progenitor Cell Therapy (PCT)
- Need for frequent genomic monitoring of pluripotent stem cells
- Neo-Urinary Conduit
- NeoStem
- NeoStem (AMEX: NBS)
- NeoStem (NYSE MKT: NBS)
- Nerve Regeneration
- Neural Stem Cell Therapy
- Neuralstem (AMEX:CUR)
- Neuralstem (AMEX; CUR)
- Neuralstem (NYSE MKT: CUR)
- New ASTM Analyst Review
- New board member
- New Cell Banking Services
- New Cell Lines
- New Cell Lines for Research
- New CEO and Board Member
- New Chairman
- New Chairman & CEO
- New Chairman of CIRM
- New Collaboration
- New COO and acting CEO
- New CYTX Analyst Review
- New Distribution Agreement
- New Embryome Products
- New FDA Reporting Rules
- New Findings
- New Foundational Japanese Patent
- New interim CEO
- New Lead Investor Google Ventures
- New Patent
- New Proxy
- New Scientific Advisory Board Member
- new test for genetic mutations
- New Therapeutic Approach
- New Trial Results
- New Venture Financing
- News
- News from Global Stem Cell Summit
- NHLBI Grant using iPSCs
- NIH Budget
- NIH Funding for Clinical Trials
- Nobel Prize in Medicine
- Noble Capital Markets' Life Sciences Exposition
- Non-exclusive international license
- Non-exclusive license
- Northwest Biotherapeutics (NWBO)
- Notice of Delisting
- NSI-189 IND Application
- NSI189 Safety Depressive Disorder Trial
- NurOwn™ inhibits Sciatic Nerve Injury
- Nuvilex (OTC QB: NVLX)
- NYSE Amex: BTIM
- NYSE Amex: IMUC
- NYSE Amex: NBS
- OncoCyte Corporation
- OncoMed Pharmaceuticals
- Opening the Door to India
- Opexa Therapeutics (OPXA)
- Opinion
- Orphan Drug designation
- Orphan Drug Designation (ODD)
- Orphan Drug Status
- Orthopedic Collaboration
- orthopedic regenerative medicine/biotechnology company
- OSIR Rebounds
- OSIR strengthens mngt team
- OSIR trends higher again
- Osiris Therapeutics
- OTC:BB:ACTC
- Our Stem Cells: The Mystery of Life and Secrets of Healing
- P1 Heart attack trial of its stem cell therapy
- P1 PISCES safety clinical trial
- P2 imetelstat (GRN163L) trial
- P2b RESTORE-CLI Webcast
- P3 study of HA-Irinotecan in metastatic colorectal (bowel) cancer
- Parkinson disease
- Parthenogenesis could treat Inherited Disease
- Parthenogenetic Stem Cell Patent
- Partners with Vatican’s Pontifical Council
- Patent and know-how license agreement with Schepens Eye Research Institute
- Patent Issuance
- Patent Issues
- Patent trouble Ahead?
- Patents
- Patient Enrollment in REVIVE P3 Clinical Trial of Ixmyelocel-T
- Patient Protection and Affordable Care Act of 2010
- Patients with head and neck cancers
- Pay OK for Blood-Based Marrow Cell Donors
- Pelizeaus-Merzbacher Disease (PMD)
- peripheral arterial disease
- Personalized Medicine
- personalized treatment.
- Phase 2 IMPACT-DCM clinical trial extension study
- Phase I clinical trial of MultiStem(R)
- Phase I/II trial
- Phase Ib trial
- Phase II trial clearence
- Phase II/III Clinical Trial in CLI Advances
- Phase IIb TERMS clinical trial
- PI dendritic cell cancer clinical trial
- PI Study of MultiStem
- PII clinical trial for stroke
- Plasticell
- pluripotent stem cell patents
- pluripotent stem cell products
- pluripotent stem cells
- Pluristem (PSTI)
- Pluristem Therapeutics
- Politics
- Positive 12-month final results from the RESTORE-CLI Phase 2 clinical trial
- Positive clinical trials of its adult stem cell product
- Positive Interim Safety Data from Spinal Cord Injury Trial
- Positive P2 Data for Autologous Treatment
- Positive Pre-Clinical Data from Muscle Injury Study
- Positive Results from Phase I Study of MultiStem(R) in Heart Attack Patients
- Positive Results of Bone Marrow Regeneration Trial
- Potential targets for new cancer drugs
- Potential Treatment of Radiation Exposure
- PPACA Grant
- Prader-Willi Syndrome
- pre-CTA consultation meeting
- Preclinical Acute Kidney Injury Study
- Preclinical Results
- Preclinical Study Data of GRNCM1
- Printing Human Skin
- Product Aquisitions
- Progenitor Cell Therapy (PCT) adds to Management
- Promise for Epileptics
- Proposed Public Offering
- Prospectus to register Shares
- Prostate Cancer
- protein-induced pluripotent stem (iPS) cells
- Proteins Found in Muscle Tissue
- Provide stem cell and cancer researchers with leading-edge technologies
- Proxy for Reverse Split
- Prudent Shelf Filing
- Public offering
- Public Offering closes
- Public Offering Completed
- purchase warrants offered
- PureGraft™ System
- Purifying Embryonic Stem Cells
- PwC/NVCA MoneyTree Report
- Q1/11 Results
- Q1/12 Earngs
- Q2 Earnings
- Q2/11 earnings
- Q3/10 Results
- Q3/10 Venture Funding
- Q3/11 Results
- Q3/12
- Q4/10 and FY/10 Results
- Q4/10 results
- Q4/11 and FY 11 Results
- Q4/11 and FY11 Results
- Q4/12 and FY12 Results
- QTDP grants
- Qualifying Therapeutic Discovery Program (QTDP)
- Qualifying Therapeutic Discovery Project
- Quarterlly Achievements
- Quarterly Achievements
- Quarterly Earnings
- Radiation exposure
- Re-nominating Process
- Re-nomination of Bob Klein
- Red Blood Cells from IVF Embryos
- Refocusing cancer research
- Regenerative benefits of MultiStem's therapy
- Regenerative Medicine
- Regenerative Medicine Mid-Week Trend Line
- Regenerative Medicine Promotion Act of 2010
- Regenerative Medicine Weekly Trend Line
- REGENESIS-Phase IIb stroke trial
- Regenicin (OTC BB: RGIN)
- Registered Direct Offering
- RegMed Competitive and Market Intelligence
- RegMed Daily
- RegMed Daily – The Early Movers
- RegMed Daily Closing Bell
- RegMed Daily Dialogue
- RegMed Daily Mid-Day
- RegMed Daily Pre-Open
- RegMed Sector: 10 things you should know of … this morning
- Regulatory Initiatives
- ReNeuron (LON: RENE)
- ReNeuron (LSE:RENE.L)
- Reneuron Group
- ReNeuron Group (RENE.L)
- Repairing cardiac muscles
- Replicating Real Skin
- Replicating the complexity of an organ
- Report Card
- Res-Q™60 BMC System
- Research Note
- Researchers need reliable stem-cell supplies
- Restatement Reclassifies Warrants
- RESTORE-2 study
- RESTORE-CLI trial
- Restoring Partial Spine Mobility
- Retinal Disease Studies
- retinal pigment epithelium (RPE)
- Revascor (TM)
- Reverse stock split
- rheumatoid arthritis
- Roche
- Roche and UCLA Agreement
- Rod Raynovich – Contributor
- Rodman & Renshaw
- Salk Institute for Biological Studies
- Sangamo Biosciences (SGMO)
- SC Proven product Portfolio
- Scale-up initiated
- Science Briefs
- SCRO Approval
- Sector Analysis
- Secured Loan Facility
- Sept4/ARTS pathway
- Series B Venture Financing
- Setback for New Stem Cell Treatment
- Settleing errors involving warrant issuances
- Shelf Filing up to $75M
- Sherley v. Sebelius
- Sherley v. Sebelius case
- Shire
- Short Sellers
- Shutting down cell division could lead to new cancer drugs.
- Sigma-Aldrich
- Signaling Pathways
- Single-blastomere technology Patent
- Sistemic
- Skin Rejuvenation Crèmes
- Sox9
- SPA Agreement
- SPA submitted to FDA
- special protocol assessment (SPA) process
- Spinal Cord Injury Trial
- Stem Cell Banking
- Stem cell breakthrough
- Stem Cell centers for Innovation
- Stem Cell Data to Repair Brain Damage
- Stem cell differentiation protocols
- Stem Cell Disorders
- Stem Cell Gene Linked to Leukemia and Other Cancers
- Stem Cell Line Litigation
- Stem Cell Market
- Stem Cell Research
- Stem Cell Research Advancement Act
- Stem Cell Skin Gun for wound care
- Stem Cell Study helps Clarify the Best Time for Therapy to Aid Heart Attack Survivors
- Stem Cell Technology
- Stem Cell Therapeutic and Research Act
- Stem Cell Therapeutic and Research Reauthorization Act
- Stem Cell Therapeutics (TSX: VENTURE SSS)
- stem cell therapy for severe kidney disease
- Stem Cell Trial in Spinal Cord Injury
- Stem Cell/Regenerative Medicine Universe Earnings
- Stem cells can be targeted in their fight against liver cancer
- Stem Cells Go to War
- Stem for Life Foundation
- Stem Line Litigation
- Stembancc
- StemCellRegenMed
- StemCells
- StemCells (STEM)
- Stemedica
- Stemedica Cell Technology
- Stemgent
- Stemline Therapeutics
- Stemline Therapeutics (STML)
- Stemming
- Stemming by the Glass
- Steve Brozak
- strategic alliance
- strategic equity agreement
- Strategic Equity Agreement Closes
- Strengthened management team
- Suppressing a protein in the blood
- Supreme Court ruling
- Susan G Komen for the Cure
- SynGen
- Synthetic Biology
- Targeting Ischemic Diseases by Improving Blood Flow
- Tay-Sachs disease
- telomerase inhibitor drug
- Temusi CLI phase III Trial Fails
- Tengion
- Tengion (OTC: TNGN)
- TENGION (TNGN-0)
- The Alliance for Regenerative Medicine
- The Daily Dialogue
- The Daily Look
- The Intellectual Property Value
- The issue of liability claims
- The president’s proposed budget
- The RegMed Daily Dialogue
- The Roslin Institute
- The Stem Cell Therapeutic and Research Reauthorization Act of 2010
- The Trend is your Friend
- The Vatican
- The Vatican Response
- The Week: August 2-6/10
- Therapeutic Discovery Project
- Therapeutic Discovery Tax Credit
- Theresa "Tracy" Deisher
- ThermoGenesis (KOOL)
- Thomas B. Okarma Leaves as CEO
- Ticker Symbol Change
- TiGenix (NYSE Euronext: TIG)
- TiGenix (TIG) combination with Cellerix
- TiGenix combination with Cellerix
- TikoMed AB
- TNGN
- Tovaxin® for multiple sclerosis (MS)
- Tracy T. Lefteroff
- Transcription Factors play a role in maintaining Blood Stem Cells
- Transdifferentiation Platform
- Transposagen Biopharmaceuticals
- Treating bowel cancer
- Treating corneal blindness and vision impairment
- Treatment of diabetic foot ulcers and other chronic wounds
- Tribute to an Investment King and Legend
- TSX VENTURE: SSS
- UCSD Awards
- UCSF expanding hESC research
- UK Cancer Stem Cell Consortium
- UK NHS National Innovation Centre
- UMass’ Medical School's Human Stem Cell Bank and Registry
- Uncategorized
- universal red blood cells and platelets
- University of Michigan Comprehensive Cancer Center
- University of Minnesota‘s Masonic Cancer Center
- Unsolicited proposal from TSE:VRX re CEPH
- Update on Neo-Urinary Conduit Clinical Trial
- Updating Skin Care product
- US Army Grant for Traumatic Wounds
- US Court of Appeals for the District of Columbia
- US Patent and Trademark Office
- US Phase 2 IMPACT-DCM clinical trial results
- Valuation
- Vatican and NeoStem (AMEX: NBS) host Adult Stem Cell Meeting
- VEITHsymposium™ non-CME satellite session
- Venture Financing
- Venture series A financing from Bay City Capital LLC
- Verastem
- Verastem (NASDAQ: VSTM)
- ViaCyte (X-Novocell)
- VistaGen (OTCQB: VSTA)
- Vivalis (VLS.PA)
- VSEL™ Technology
- Wake Forest Institute for Regenerative Medicine
- Wall Street Letter
- Warrant Discount Offer
- warrant exercise
- WBB Securities
- William M. Caldwell IV
- Wired Magazine article
- Withdraws plans for IPO
- Worldwide exclusive license
- Wound Care
- Wright Medical Group (WMGI)
- www. Scimitar Equity.com/blog
- www.retailinvestorconferences.com
Blogroll
Regulatory Disclosure
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009